| Literature DB >> 8833060 |
Abstract
The combination of traditional disease modifying antirheumatic drugs such as methotrexate (MTX) with biologic agents for treating rheumatoid arthritis (RA) has thus far been limited. The combination of MTX and a depleting anti-CD4 monoclonal antibody (cM-T412) has been evaluated in phase I and II trials in patients with refractory RA. The potential of combining MTX with other biologic agents is reviewed.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8833060
Source DB: PubMed Journal: J Rheumatol Suppl ISSN： 0380-0903